Literature DB >> 17434848

Comparison of direct and indirect measurement of LDL-C in HIV-infected individuals: ACTG 5087.

Scott R Evans1, Carl J Fichtenbaum, Judith A Aberg.   

Abstract

BACKGROUND: Hypertriglyceridemia is common in HIV-infected individuals on antiretroviral therapy. Triglyceride (TG) levels >400 mg/dL interfere with the accurate determination of low-density lipoproteins (LDL-C) by the Friedewald equation, making it difficult to assess coronary heart disease risk.
OBJECTIVE: The objective of this study is to compare the agreement of the direct LDL-C assay and the Friedewald equation with a reference ultracentrifugation method in the estimation of LDL-C concentrations.
METHOD: Samples from ACTG 5087 were assayed by ultracentrifugation and a direct enzymatic assay and calculated using the Friedewald equation.
RESULTS: In subjects with TG <400 mg/dL (n = 271), 90% of the direct LDL-C values and Friedewald calculations were within 30 mg/dL and 32 mg/dL of the ultracentrifugation values, respectively. With TG > or = 400 mg/dL (n = 186), 90% of the direct assay and Friedewald observations were within 68 mg/dL and 120 mg/dL of the ultracentrifugation results, respectively. Only 27% of the LDL-C values were within 15 mg/dL of the ultracentrifugation LDL-C results for direct assay and 16.3% for the Friedewald equation.
CONCLUSION: The direct LDL-C assay and the calculated LDL-C values did not display adequate agreement with the reference ultracentrifugation method. In subjects with TG >400 mg/dL, the direct assay overestimates the actual LDL-C whereas the Friedewald calculation underestimates the actual LDL. Clinical usage of these methods may lead to misclassification of the severity of dyslipidemia, resulting in improper management.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17434848      PMCID: PMC2288650          DOI: 10.1310/hct0801-45

Source DB:  PubMed          Journal:  HIV Clin Trials        ISSN: 1528-4336


  25 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

Review 2.  HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management.

Authors:  Andrew Carr
Journal:  AIDS       Date:  2003-04       Impact factor: 4.177

Review 3.  Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.

Authors:  Carl J Fichtenbaum; John G Gerber
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management.

Authors:  G Assmann
Journal:  Am J Cardiol       Date:  2001-03-08       Impact factor: 2.778

5.  HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus.

Authors:  T M Riddle; D G Kuhel; L A Woollett; C J Fichtenbaum; D Y Hui
Journal:  J Biol Chem       Date:  2001-08-23       Impact factor: 5.157

6.  Performance of four homogeneous direct methods for LDL-cholesterol.

Authors:  W Greg Miller; Parvin P Waymack; F Philip Anderson; Steven F Ethridge; Eduviges C Jayne
Journal:  Clin Chem       Date:  2002-03       Impact factor: 8.327

7.  Analytical performance and clinical efficacy of three routine procedures for LDL cholesterol measurement compared with the ultracentrifugation-dextran sulfate-Mg(2+) method.

Authors:  M Nauck; N Rifai
Journal:  Clin Chim Acta       Date:  2000-04       Impact factor: 3.786

8.  Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.

Authors:  P H Hsyu; M D Schultz-Smith; J H Lillibridge; R H Lewis; B M Kerr
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

Review 9.  Effects of HIV protease inhibitor therapy on lipid metabolism.

Authors:  David Y Hui
Journal:  Prog Lipid Res       Date:  2003-03       Impact factor: 16.195

10.  Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108.

Authors:  Judith A Aberg; Susan L Rosenkranz; Carl J Fichtenbaum; Beverly L Alston; Susan W Brobst; Yoninah Segal; John G Gerber
Journal:  AIDS       Date:  2006-03-21       Impact factor: 4.177

View more
  4 in total

1.  Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186.

Authors:  John G Gerber; Douglas W Kitch; Carl J Fichtenbaum; Robert A Zackin; Stéphannie Charles; Evelyn Hogg; Edward P Acosta; Elizabeth Connick; David Wohl; E Milu Kojic; Constance A Benson; Judith A Aberg
Journal:  J Acquir Immune Defic Syndr       Date:  2008-04-01       Impact factor: 3.731

2.  Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in Hepatitis C virus/HIV-coinfected persons: the AIDS Clinical Trials Group A5178 Study.

Authors:  Adeel A Butt; Triin Umbleja; Janet W Andersen; Kenneth E Sherman; Raymond T Chung
Journal:  Clin Infect Dis       Date:  2012-05-04       Impact factor: 9.079

3.  Effectiveness and tolerability of ezetimibe co-administered with statins versus statin dose-doubling in high-risk patients with persistent hyperlipidemia: The EZE(STAT)2 trial.

Authors:  A Shekhar Pandey; Stéphane Bissonnette; Stella Boukas; Emmanouil Rampakakis; John S Sampalis
Journal:  Arch Med Sci       Date:  2011-11-08       Impact factor: 3.318

4.  Comparison of calculated versus directly-measured low-density lipoprotein-cholesterol: An evaluation of ten formulas for an HIV-positive population in Sub-Saharan Africa.

Authors:  Ifeyinwa Osegbe; Martin Ugonabo; Chinwe Chukwuka; Ijeoma Meka; Nnamdi Nwosu
Journal:  J Lab Physicians       Date:  2017 Apr-Jun
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.